A patient with Parkinson's disease, initially treated with bromocriptine and subsequently with cabergoline, developed progressive pleuropulmonary abnormalities during the latter therapy. These lesions even worsened for some weeks after interruption of cabergoline, which may possibly be related to the prolonged action of this drug. Thus cabergoline may cause similar pleuropulmonary abnormalities to bromocriptine.
No takes yet. Share an insight, caveat, or question.
Frans et al. (1992) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: